<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02228174</url>
  </required_header>
  <id_info>
    <org_study_id>CL04502</org_study_id>
    <nct_id>NCT02228174</nct_id>
  </id_info>
  <brief_title>Sonography Guided Transcervical Ablation of Uterine Fibroids</brief_title>
  <acronym>SONATA</acronym>
  <official_title>Evaluation of the Gynesonics System for Transcervical Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation Under Integrated Intrauterine Sonography Guidance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynesonics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynesonics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the safety and effectiveness of the Sonata®
      System in the treatment of symptomatic uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single-arm study, subjects who have symptomatic uterine fibroids will have
      transcervical RF ablation of uterine fibroids under intrauterine ultrasound guidance using
      the Gynesonics Sonata System.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">October 5, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in menstrual blood loss (MBL) as assessed by pictorial blood loss assessment chart (PBAC)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in volume of menstrual blood loss at 12 months post-procedure compared to baseline as assessed by PBAC. Success is defined for individual subjects as a ≥ 50% reduction from baseline in menstrual blood loss and a final PBAC score &lt; 250.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of surgical re-intervention for heavy menstrual bleeding due to treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>Patients who had surgical reintervention for heavy menstrual bleeding due to treatment failure. Surgical reintervention success for an individual subject is defined as no surgical reintervention due to treatment failure within the 12-month post-treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse Device Effects</measure>
    <time_frame>Each follow-up visit through 36 months</time_frame>
    <description>Procedure safety will be assessed by recording all adverse device effects that occur during or subsequent to treatment on the day of the procedure. Longer-term safety will be assessed by recording at each follow-up visit any untoward medical occurrence since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in total and perfused fibroid volumes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in total and perfused volume of clinically relevant fibroids will be determined by comparing contrast-enhanced MRI at baseline and at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the symptom severity and quality of life subscales of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) Questionnaire</measure>
    <time_frame>3, 6, 12, 24, and 36 months</time_frame>
    <description>The Symptom Severity Score (SSS) and Health-Related Quality of Life Score (HRQL) are calculated from a subset of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire, a validated and fibroid-specific assessment tool. The questionnaire and the SSS component have been used in several studies of subjects with fibroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to normal daily activity (days)</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Subjects will be given a Treatment Recovery Questionnaire at discharge and asked to complete questions daily regarding return to normal activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall subject treatment outcome using the Overall Treatment Effect Scale (OTE)</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
    <description>Subject-perceived overall treatment effect (OTE) will be assessed using the OTE Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
    <description>Subjects will be asked to rate their level of satisfaction with the treatment and whether they would recommend the procedure to a friend with the same health problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in general health outcome</measure>
    <time_frame>3, 6, 12, 24, and 36 months</time_frame>
    <description>Change in general health outcome is assessed with the EuroQOL EQ-5D. The EQ-5D is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject pain and tolerance of procedure</measure>
    <time_frame>Day 0 - Treatment</time_frame>
    <description>Prior to discharge, subjects will be asked to rate their tolerance of the procedure and rate their experience of pain using a pain Visual Analog Scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean length of stay</measure>
    <time_frame>Day 0 - Treatment</time_frame>
    <description>Length of stay (in hours) will be assessed by recording the duration from the start of the procedure to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Pregnancy and Pregnancy Outcome</measure>
    <time_frame>All follow-up visits through 36 months</time_frame>
    <description>Subjects will be asked about the possible occurrence of pregnancy. If a pregnancy has occurred, information regarding pregnancy outcome will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Productivity and Activity Impairment</measure>
    <time_frame>3, 6, 12, 24, and 36 months</time_frame>
    <description>The Work Productivity and Activity Impairment questionnaire for a specific health problem (WPAI:SHP) is a standardized instrument for use in assessing productivity and activity impairment for use in health economics outcomes research.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>Sonography guided transcervical ablation of uterine fibroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sonography guided transcervical ablation of uterine fibroids with the Gynesonics Sonata system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrauterine Ultrasound-Guided Radiofrequency Ablation System</intervention_name>
    <description>The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended to provide focal treatment of symptomatic fibroids responsible for heavy menstrual bleeding (HMB).</description>
    <arm_group_label>Sonography guided transcervical ablation of uterine fibroids</arm_group_label>
    <other_name>Gynesonics Sonata System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal

          -  ≥ 25 and ≤ 50 years of age at time of enrollment

          -  experienced heavy menstrual bleeding associated with fibroids (AUB-L) for at least 3
             months

          -  between 1-10 fibroids of FIGO types 1, 2, 3, 4, and/or type 2-5, with diameter ≥ 1.0
             cm and ≤ 5.0 cm

          -  at least one type 1, type 2, type 3, or type 2-5 fibroid.

          -  PBAC score ≥ 150 and ≤ 500

          -  consistent menstrual cycles

          -  not at material risk for pregnancy

          -  speaks and reads a language for which validated questionnaires are available

          -  willing and able to read, understand, and sign the informed consent form, to
             participate in the study and to adhere to all study follow-up requirements

        Exclusion Criteria:

          -  pregnancy

          -  urgent need for surgery to treat fibroid symptoms

          -  desire for current or future childbearing

          -  presence of a tubal implant for sterilization

          -  postmenopausal by history

          -  presence of type 0 fibroids, unless &lt; 1 cm in diameter

          -  presence of a single polyp ≥ 1.5 cm, or multiple polyps of any size

          -  any fibroid of FIGO type 1, type 2, type 3, type 4, or type 2-5 with diameter &gt; 5.0 cm

          -  bulk symptoms in the presence of one or more fibroids of FIGO type 5, type 6, or type
             7

          -  exclusive presence of fibroids that are insufficient to explain the severity of
             symptoms

          -  presence of clinically relevant fibroids that cannot be treated for technical reasons

          -  presence of an extrauterine pelvic mass that has not been diagnosed as benign

          -  IUD/IUS in situ within the washout period

          -  previous procedure for fibroids or heavy menstrual bleeding other than myomectomy

          -  myomectomy within 12 months

          -  any abnormality of the endometrial cavity that obstructs access of the handpiece

          -  contraindication to MRI

          -  total uterine volume &gt; 1000 cc

          -  clinically significant adenomyosis

          -  confirmed or suspected diagnosis of clinically relevant endometriosis

          -  one or more clinically relevant fibroids that are significantly calcified.

          -  previous pelvic irradiation

          -  renal insufficiency [serum creatinine ≥ 1.5 mg/dL (132.6 μmol/L)]

          -  evidence of disorders of hemostasis (AUB-C)

          -  abnormal cervical cytology that is unevaluated or untreated in adherence with national
             guidelines

          -  endometrial hyperplasia (AUB-M), including simple hyperplasia without atypia

          -  confirmed abdominal / pelvic malignancy within the previous five years

          -  active pelvic infection or current positive testing for pelvic gonorrhea or chlamydia;

          -  use of a hormonally-relevant medication within the washout period

          -  use of an antifibrinolytic agent while undergoing any screening procedures

          -  current use of anticoagulant therapy

          -  chronic pelvic pain (disruptive for at least six months) or significant baseline
             pelvic or menstrual pain

          -  chronic uncontrolled moderate and severe hypertension

          -  hypoplastic or otherwise short uterus

          -  major medical or psychiatric illness or other factors that may affect general health
             or subject's ability to adhere to the follow-up schedule or provide valid subject
             self-assessment data

          -  any other reason for which the individual study subject is not appropriate or suitable
             for participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kelly H. Roy M.D. P.C.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Women's Health Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services, Inc.</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO Clinical Research, LLC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Advanced Gynecologic Surgery Institute - Charles E. Miller, MD &amp; Associates</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic, Minimally Invasive Gynecology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basque Women's Care</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Women's Research and Wellness Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Women's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willowbend Health and Wellness Associates</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. José Eleuterio González&quot; de la Universidad Autónoma de Nuevo León</name>
      <address>
        <city>Monterrey</city>
        <state>N.l.</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abnormal Uterine Bleeding associated with fibroids</keyword>
  <keyword>AUB-L</keyword>
  <keyword>Fibroids</keyword>
  <keyword>Heavy menstrual bleeding</keyword>
  <keyword>HMB</keyword>
  <keyword>Myoma</keyword>
  <keyword>Menorrhagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zaleplon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

